Literature DB >> 7584935

Possible linkage between renal injury and cardiac remodeling in Dahl salt-sensitive rats treated with the calcium channel antagonist benidipine.

Y Uehara1, N Hirawa, T Takeda, A Numabe, Y Kawabata, H Nagoshi, T Gomi, J Ikegami, A Goto, M Omata.   

Abstract

Interest in cardiovascular protection by calcium channel antagonists has grown over the past decade. We investigated the prevention of cardiac remodeling and renal injury by the long-acting calcium channel antagonist benidipine using 12 week-old Dahl salt-sensitive (Dahl S) rats fed a high-salt (4% NaCl) diet. Six-week benidipine treatment (10 mg/kg chow) decreased systolic blood pressure by 22% in Dahl S rats. This blood pressure reduction was associated with decreases in cardiac mass and weight of the aortic wall. Collagen content in the left ventricle tended to decline with benidipine treatment. In addition, glomerular filtration rate increased by 33% and arterial and glomerular lesions improved morphologically with this treatment. Regression of cardiac mass and collagen content in the left ventricle was due mainly to blood pressure reduction; however, collagen content in the low-pressure right ventricle was not only related to systemic blood pressure but to the severity of renal lesions. These data suggest that the calcium channel antagonist benidipine attenuates cardiac and renal injury in hypertensive Dahl S rats, and that part of the cardiac hypertrophy is due to a non-hemodynamic mechanism that might be responsible for, or be a consequence of, the lesions in the kidney.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7584935     DOI: 10.1291/hypres.18.245

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  1 in total

1.  Newly manufactured Marukome MK-34-1 miso with angiotensin-converting enzyme inhibitory activity and its antihypertensive effects in genetic hypertensive rat models.

Authors:  Hiroe Sakuyama Tomari; Misa Uchikawa; Aki Yamazaki; Satomi Hirabayashi; Shoko Yamakawa; Manabu Kitagawa; Minami Yamada; Seiki Itou; Tetsuro Yamamoto; Yoshio Uehara
Journal:  Hypertens Res       Date:  2019-01-10       Impact factor: 3.872

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.